论文部分内容阅读
目的探讨血浆EBV-DNA拷贝数在儿童与青少年鼻咽癌的诊断意义与预后分析。方法回顾性收集161例儿童与青少年鼻咽癌患者治疗前后的EBV-DNA拷贝数的数值,分析其与总生存、无复发生存、无转移生存的关系。结果161例儿童与青少年鼻咽癌患者中,有69.6%的EBV-DNA为阳性结果。在非Ⅳb期患者中,发现治疗前EBV-DNA表达对总生存(P=0.400)、无复发生存(P=0.659)和无转移生存(P=0.774)差异均无统计学意义。在非Ⅳb期患者中,进行诱导化疗后,阴性组较阳性组有更好的无转移生存(P=0.001)。在非Ⅳb期患者中,进行放疗后,EBV-DNA拷贝数为0与>0比较,无论是总生存(P=0.001)、无复发生存(P<0.001)还是无转移生存(P<0.001),拷贝数为0组均获得更好的生存。结论儿童与青少年鼻咽癌治疗结束时EBV-DNA拷贝数可预测生存。
Objective To investigate the diagnostic value and prognosis of plasma EBV-DNA copy number in children and adolescents with nasopharyngeal carcinoma. Methods The data of EBV-DNA copy number in 161 children and adolescents before and after treatment were retrospectively collected. The relationship between EBV-DNA copy number and total survival, recurrence-free survival and metastasis-free survival were analyzed. Results Of 161 children and adolescents with nasopharyngeal carcinoma, 69.6% of EBV-DNA positive results. In non-IVb patients, EBV-DNA expression was found to have no significant difference between overall survival (P = 0.400), non-recurrence survival (P = 0.659) and metastasis-free survival (P = 0.774) before treatment. In non-IVb patients, after induction chemotherapy, the negative group had a better metastasis-free survival than the positive group (P = 0.001). In non-IVb patients, EBV-DNA copy number was 0 compared with> 0 after radiotherapy, regardless of overall survival (P = 0.001), relapse-free survival (P <0.001) , Copy number 0 group are better survival. Conclusions EBV-DNA copy number predicts survival at the end of treatment for children and adolescents with nasopharyngeal carcinoma.